http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jaehee Mun ),( Seokyung Kim ),( Eun Ji Lee ),( Soo Jin Park ),( Joo-hyuk Son ),( Maria Lee ),( Tae-wook Kong ),( Hee Seung Kim ),( Jiheum Paek ),( Hyun Hoon Chung ),( Suk-joon Chang ),( Jae Weon Kim 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Cremophor-free polymeric micelle formulation of paclitaxel (Genexol-PM) plus carboplatin (PM/C) has been reported to have a non-inferior effect with tolerable toxicities when compared to the standard paclitaxel plus carboplatin (P/C) in ovarian cancer. However, there is still a lack of evidence on the effect of an increased dose of paclitaxel in PM/C, especially, when compared to P/C and paclitaxel plus carboplatin with bevacizumab (P/C/B) in advanced high-grade serous ovarian cancer (HGSO). Thus, we performed a prospective cohort study on PM/C and compared the effect of PM/C with historical control of P/C and P/C/B in HGSO. Methods: We performed a prospective cohort study between October 2015 and June 2019. Patients aged 20 or more years with FIGO stage III-IV HGSO who received PM (260 mg/m<sup>2</sup>)/C (AUC 5) after primary debulking surgery (PDS) were enrolled. We collected clinico-pathologic data from a retrospective cohort when P (175 mg/m<sup>2</sup>)/C (AUC 5) or P (175 mg/m<sup>2</sup>)/C (AUC 5)/B (15 mg/kg) were used as adjuvant treatment after PDS during the same period. Results: A total of 104 patients were enrolled, and 17, 28, and 59 received P/C, P/C/B and, PM/C respectively (Table 1). Complete response was significantly highest in PM/C (29.4 vs. 39.3 vs. 61%, P=0.030; Table 1). Progression-free survival was longest in PM/C (Figure 1) and multivariate analysis showed that gross residual tumor after PDS and P/C were poor prognostic factors (adjusted hazard ratios, 2.415 and 2.751; 95% confidence intervals, 1.172-4.976 and 1.214-6.236; Table 2). Even after adjustment of the patient pool to those with no gross residual tumor after PDS, multivariate analysis still showed that P/C lowered the survival curve (adjusted hazard ratio, 3.342; 95% confidence interval, 1.143-9.777; Table 2). Conclusion: This interim analysis showed that PM/C had a comparable effect to P/C/B for stage III-IV HGSO patients who received optimal cytoreduction during PDS.
Development of a Novel Prototype Nozzle for Pressurized Intraperitoneal Aerosol Chemotherapy
( Jaehee Mun ),( Whasun Lim ),( Ji Yeon Ahn ),( Gwonhwa Song ),( Byeong-cheol Kang ),( Suk Joon Chang ),( Jung Chan Lee ),( Jeong Mook Lim ),( Hee Seung Kim ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative option for treating peritoneal carcinomatosis (PC). However, even with its clinical advantages, the current PIPAC system still suffers from limitations regarding area of drug distribution and penetration depth. Thus, we evaluated another PIPAC system using a novel prototype, and compared its performance to results of previous studies related to the current MIP. However, the comparison was only done indirectly as this system is currently not available for purchase in the market. Methods: The developed prototype includes a syringe pump, nozzle, and controllers (Figure 1). Drug distribution was evaluated using a methylene blue solution while the penetration depth was assessed by conducting an ex-vivo experiment with porcine tissues in a 3.5l plastic box. Doxorubicin was sprayed using the novel prototype, and its penetration depth was investigated by confocal laser scanning microscopy. The experiment was repeated with varying nozzle levels beginning from the bottom. The novel prototype sprayed approximately 30 m drug droplets at a flow rate of 30 ml/min with 7 bars of pressure. Results: The average diameter of sprayed region with concentrated dye was 18.5±1.2 cm, which was comparable to that of the current MIP (about 10 cm; Figure 1). The depth of concentrated diffusion (DCD) did not differ among varying nozzle levels, whereas the depth of maximal diffusion (DMD) decreased with increasing distance between the prototype and the bottom (mean values, 515.3 um at 2 cm; 437.6 um at 4 cm; 363.2 um at 8 cm), which was comparable to those of the current MIP (about 350-500 um; Figure 2). Conclusion: We developed a novel prototype that can generate small droplets for drug aerosolization and can produce an equally widely sprayed area and deep penetration compared to the current MIP but at a lower pressure.
Rosai-Dorfman disease coexisting with ovarian tumor, mimicking metastatic ovarian cancer
( Jaehee Mun ),( Joon Hyung Lee ),( Jeong Yun Kim ),( Hye Won Jeon ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Rosai-Dorfman disease (RDD) is a rare systemic histiocytic disease that infiltrates lymph nodes and extranodal sites usually in children and young adults. Typically, such patients present with fever and painless cervical lymphadenopathy. We present a case of a 68-year-old postmenopausal woman who visited the gynecology clinic with abdominal pain as her chief complaint. Imaging evaluation with abdomen-pelvis computed tomography (CT), pelvic magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT showed a huge hypermetabolic ovarian tumor with an enlarged para-aortic lymph node which was suspicious of ovarian cancer with lymph node metastasis (Figure 1). After work-up, total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, and enlarged para-aortic lymph node excision were performed. Histopathologic diagnosis showed a sclerosing stromal tumor of ovary coexisting with RDD of para-aortic lymph node, of which cells from para-aortic lymph nodes were immunohistochemically positive for S-100 and CD68, common markers of RDD (Figure 2). Although complete excision was done, routine follow-up a year later revealed recurrent metastatic lymphadenopathy and lung metastasis of RDD. Although RDD is known as a non-malignant disease, disease-related complications, such as obstruction of adjacent organs or infection, can lead to a poor outcome. Likewise, this patient was eventually transferred to another institution solely for supportive care. Thus, although RDD does not occur commonly, it is important to recognize that such diseases can mimic metastatic ovarian cancer. This would help in not only the differential diagnosis of ovarian cancer, but also quickly diagnosing and treating the patient accordingly as treatment guidelines for each disease can differ greatly.
Hur Young Min,Mun Jaehee,Kim Mi-Kyung,Lee Maria,Kim Yun Hwan,Kim Seung-Cheol 대한의학회 2021 Journal of Korean medical science Vol.36 No.38
Background: To assess the rate of germline BRCA gene tests in epithelial ovarian cancer (EOC) patients and uptake of post-test risk management strategies in BRCA1/2-mutated patients. Methods: Institutional databases were searched to identify patients who were diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) between 2009 and 2019 in two academic hospitals. Retrospective review on medical records was performed to collect clinico-pathologic variables, including performance of germline BRCA gene test and its results, as well as conduct of breast cancer screening tests and cascade testing. If annual mammography +/− breast ultrasonography was performed, it was considered that regular breast cancer surveillance was done. Results: A total of 840 women with EOC were identified during the study period. Of these, 454 patients (54.0%) received BRCA gene testing and 106 patients (106/454, 23.3%) were positive for BRCA1/2 mutations. The rate of BRCA tests has markedly increased from 25.8% in 2009- 2012 to 62.7% in 2017-2019. Among the 93 patients with BRCA1/2 mutation without previous personal breast cancer history, 20 patients (21.5%) received annual mammography with or without breast ultrasonography for regular surveillance. Among the 106 BRCA1/2-mutated EOC patients, cascade testing on family members was performed only in 13 patients (12.3%). Conclusion: Although BRCA1/2 gene tests have been substantially expanded, the uptake of post-test risk management strategies, including breast cancer screening for BRCA1/2-mutated patients and cascade testing for family members, has remained low. Strategies to increase its uptake and education about the importance of post-test risk managements are needed.
H<sub>2</sub>O<sub>2</sub>-induced up-regulation of CatSper3 in mouse brain
Kim, Chang-Woon,Tak, Hyun-Min,Kim, Gyu-Tae,Mun, Yun-Ja,Jeon, Byeong Tak,Kim, Hyun Joon,Roh, Gu Seob,Han, Jaehee,Kang, Dawon Wiley Subscription Services, Inc., A Wiley Company 2010 Molecular reproduction and development Vol.77 No.8
박수진 ( Soo Jin Park ),( Eun Ji Lee ),( Hee Su Lee ),( Junsik Kim ),( Sunwoo Park ),( Jiyeon Ham ),( Jaehee Mun ),( Haerin Paik ),( Hyunji Lim ),( Aeran Seol ),( Ga Won Yim ),( Seung-hyuk Shim ),( Beong 대한산부인과학회 2022 대한산부인과학회 학술대회 Vol.108 No.-
This study aims to evaluate the drug distribution, tissue concentrations, penetration depth, pharmacokinetic properties, and toxicities after rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) in pigs. Because relevant medical devices have not been introduced, we developed our prototype of pressurized intraperitoneal aerosol chemotherapy (PIPAC) and RIPAC by adding a conical pendulum motion device for rotating the nozzle. RIPAC and PIPAC were conducted using 150 ml of 1% methylene blue to evaluate the drug distribution and 3.5mg of doxorubicin in 50 ml of 0.9% NaCl to evaluate the tissue concentrations and penetration depth, pharmacokinetic properties, and toxicities. All agents were sprayed as aerosols via the nozzle, DreamPenVR (Dalim Biotech, Gangwon, South Korea), with a velocity of 5 km/h at a flow rate of 30 ml/min under a pressure of 7 bars, and capnoperitoneum of 12mmHg was maintained for 30 min. As a result, RIPAC showed a wider distribution and stronger intensity than PIPAC. Compared with PIPAC, RIPAC demonstrated high values of the tissue concentration in the central, right upper, epigastrium, left upper, left lower, right lower, and right flank regions (median, 375.5-2124.9 vs. 161.7- 1240 ng/ml; p_ .05), and higher values of the depth of concentrated diffusion and depth of maximal diffusion (median, 232.5- 392.7 vs. 116.9-240.1 lm; 291.2-551.2 vs. 250.5-362.4 lm; p_ .05) in all regions except for bowels. In RIPAC, the pharmacokinetic properties reflected hemodynamic changes during capnoperitoneum, and there were no related toxicities. Conclusively, RIPAC may have the potential to enhance drug delivery into the peritoneum compared to PIPAC.